mRNA technology for vaccines and more: An Ars Frontiers recap
Enlarge / On May 22, John Timmer (left) moderated a panel featuring Karin Bok (center) and Nathaniel Wang (right) for the Ars Frontiers 2023 session titled, "Beyond COVID: What Does mRNA Technology Mean for Disease Treatment?" (credit: Ars Technica)
The world of biomedicine has developed a lot of technology that seems a small step removed from science fiction, but the public isn't aware of much of it. One of those technologies, mRNA-based vaccines, however, has been a big exception, as a lot of the public tracked the technology's development as a key step toward emerging from the worst of the pandemic and then received the vaccines in droves.
mRNA technology has a lot of potential applications beyond COVID, and we talked a bit about those during the "Beyond COVID: What Does mRNA Technology Mean for Disease Treatment?" panel at last week's Ars Frontiers event. We've archived the panel on YouTube; if you want to focus on the discussion about mRNA therapies, you can start at the 1-hour, 55-minute mark.
mRNA is a nucleic acid molecule that instructs the cell to make specific proteins. When used as vaccines, the instructions call for a protein produced by a pathogen, such as a virus. "It helps put up a wanted poster for the immune system," was how Nathaniel Wang, co-founder and CEO of Replicate Bioscience, put it.